Molecular mechanisms of leukemic cell differentiation and apoptosis by retinoids.

类视黄醇白血病细胞分化和凋亡的分子机制。

基本信息

项目摘要

The biological effects of retinoic acid (RA) are mediated by two distinct families of transcription factors : retinoic acid receptors (RARs) and retinoid X receptors (RXRs). and RXRs and RXRs from heterodimers and regulate retinoid-mediated gene expression. We have developed several series of novel synthetic retinoid receptor agonists and antagonists that selectively interact with RXR/RXR homodimers and RAR/RXR heterodimers. Using these compounds, we demonstrated that the RAR/RXR pathway is more important for differentiation and proliferation of leukemic cells. We also showed the RAR-mediated signaling pathway is important for differentiation and apoptosis of myeloid leukemic cells. Simple activation of RXRs is not sufficient to induce apoptosis of the cells. Furthermore, HL-60 cells transduced with bcl-2 expression vector showed the same differentiationresponse to retinoids as did parental HL-60 cells even though apoptosis was inhibited in these bcl-2 transduced cells, suggesting that differentiation and apoptosis are regulated independently in myeloid leukemic cells. To understand the mechanisms and identify novel approaches to overcome RA-resistance in acute promyelocytic leukemia (APL), we established the first RA-resistant APL cell line (UF-1) and human RA-resistant mouse model in SCID mice. These cell line and animal models may be useful for investigating the biology of myeloid leukemia in vitro and in vivo, as well as for evaluating novel therapeutoc approaches including patients with RA-resistant APL.
视黄酸(RA)的生物学效应由两个不同的转录因子家族介导:视黄酸受体(RARs)和类维生素A X受体(RXRs)。以及来自异二聚体的RXR和RXR,并调节类视色素介导的基因表达。我们已经开发了几个系列的新型合成类视色素受体激动剂和拮抗剂,选择性地与RXR/RXR同源二聚体和RAR/RXR异源二聚体相互作用。使用这些化合物,我们证明RAR/RXR途径对白血病细胞的分化和增殖更重要。我们还发现RAR介导的信号通路在髓系白血病细胞的分化和凋亡中起重要作用。RXR的简单激活不足以诱导细胞凋亡。此外,转染bcl-2表达载体的HL-60细胞对类维生素A的分化反应与亲本HL-60细胞相同,尽管这些转染bcl-2的细胞中的凋亡被抑制,这表明在髓性白血病细胞中分化和凋亡是独立调节的。为了了解急性早幼粒细胞白血病(APL)中RA耐药的机制并寻找克服其耐药性的新方法,我们建立了第一个RA耐药的APL细胞系(UF-1)和人RA耐药的SCID小鼠模型。这些细胞系和动物模型可能是有用的研究在体外和体内的髓系白血病的生物学,以及评估新的治疗方法,包括RA耐药APL患者。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Yamato K,et al: "Induction of G1 arrest by activin A via cooperative modulation of cyclin D2 and p21^<CIP1/WAF1> in plasmocytic cells." Mol.Endocrinol.11. 1044-1052 (1997)
Yamato K 等人:“通过协同调节浆细胞中的细胞周期蛋白 D2 和 p21^<CIP1/WAF1>,激活素 A 诱导 G1 期停滞。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Watanabe R,et al: "Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia." Thromb.Haemostasis. 77. 641-645 (1997)
Watanabe R 等人:“用全反式视黄酸治疗急性早幼粒细胞白血病缓解诱导治疗期间止血分子标志物的长期随访。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nagao K, et al: "Skin infiltrations in acute promyelocytic leukemia." Dematology. 194. 168-171 (1997)
Nagao K 等人:“急性早幼粒细胞白血病的皮肤浸润。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kizaki M,et al: "Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid resistant features." Blood. 88. 1824-1833 (1996)
Kizaki M 等人:“具有视黄酸抗性特征的新型急性早幼粒细胞白血病细胞系 (UF-1) 的建立和表征。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Matsushita H, et al: "Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells." Blood. in press.
Matsushita H 等人:“MDR1 核酶在视黄酸抗性骨髓白血病细胞中恢复类视黄醇敏感性。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KIZAKI Masahiro其他文献

KIZAKI Masahiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KIZAKI Masahiro', 18)}}的其他基金

Development of new therapeutic approach for multiple myeloma targeted against biological properties of bone marrow microenvironment
针对骨髓微环境的生物学特性开发多发性骨髓瘤新治疗方法
  • 批准号:
    24591409
  • 财政年份:
    2012
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel molecular-targeting therapy for multiple myeloma against its progenitor cells
开发针对多发性骨髓瘤祖细胞的新型分子靶向疗法
  • 批准号:
    21591219
  • 财政年份:
    2009
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of human leukemic stem cell by reactive oxygen species (ROS) and its therapeutic applications in the clinics
活性氧(ROS)对人白血病干细胞的调控及其临床治疗应用
  • 批准号:
    19591137
  • 财政年份:
    2007
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of new molecular-targeted therapy for leukemia mediated through HIF-1 regulation by ROS
ROS介导的HIF-1调控白血病新分子靶向治疗的建立
  • 批准号:
    17591010
  • 财政年份:
    2005
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of novel differentiation-inducing therapy for leukemia with hematopoietic growth factors and arsenic trioxide
造血生长因子和三氧化二砷新型白血病诱导分化疗法的建立
  • 批准号:
    13671083
  • 财政年份:
    2001
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of apoptosis and differentiation induced by arsenic trioxide in leukemic cells and its clinical application
三氧化二砷诱导白血病细胞凋亡和分化的机制及其临床应用
  • 批准号:
    11671015
  • 财政年份:
    1999
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of retinoic acid receptor in normal and leukemic bone marrow stromal cells
视黄酸受体在正常和白血病骨髓基质细胞中的作用
  • 批准号:
    05670929
  • 财政年份:
    1993
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Rethinking the retinoic acid receptor: a revisionary view of the rapid pathways triggered
重新思考视黄酸受体:对触发的快速途径的修正观点
  • 批准号:
    2281971
  • 财政年份:
    2021
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Studentship
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    10019450
  • 财政年份:
    2019
  • 资助金额:
    $ 1.6万
  • 项目类别:
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    9896234
  • 财政年份:
    2019
  • 资助金额:
    $ 1.6万
  • 项目类别:
Involvement of retinoic acid receptor in COPD exacerbation
视黄酸受体参与 COPD 恶化
  • 批准号:
    19K17625
  • 财政年份:
    2019
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Application of artificial intelligence-driven design of function-directed ligands for selective retinoic acid receptor binding
应用人工智能驱动的功能导向配体设计选择性视黄酸受体结合
  • 批准号:
    2281994
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Studentship
Elucidation of anti-obese mechanism via the retinoic acid receptor signal controlled by SMRT
通过 SMRT 控制的视黄酸受体信号阐明抗肥胖机制
  • 批准号:
    18K08486
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Application of artificial intelligence-driven design of function-directed ligands for selective retinoic acid receptor binding
应用人工智能驱动的功能导向配体设计选择性视黄酸受体结合
  • 批准号:
    BB/S507350/1
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Training Grant
NPIF Application of Artificial Intelligence-Driven Design of Function-Directed Ligands for Selective Retinoic Acid Receptor Binding
NPIF 应用人工智能驱动的功能导向配体设计进行选择性视黄酸受体结合
  • 批准号:
    2116078
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Studentship
Application of Artificial Intelligence-Driven Design of Function-Directed Ligands for Selective Retinoic Acid Receptor Binding
应用人工智能驱动的功能导向配体设计选择性视黄酸受体结合
  • 批准号:
    2104260
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Studentship
A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury
视黄酸受体β激动剂治疗脊髓损伤的一期试验
  • 批准号:
    MR/R006466/1
  • 财政年份:
    2018
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了